StonvexLoading…
StonvexStonvexStonvexCore line items from NUS's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $320.61M | $1.49B | $1.11B | $750.63M |
Operating Income | $4.03M | $65.76M | $42.52M | $20.88M |
Net Income | $1.84M | $160.20M | $145.71M | $128.63M |
EPS (Diluted) | $0.04 | $3.18 | $2.91 | $2.59 |
Total Assets | $1.38B | $1.41B | $1.42B | $1.44B |
Total Liabilities | $582.71M | $600.07M | $624.61M | $655.94M |
Cash & Equivalents | $198.65M | $238.63M | $251.79M | $264.16M |
Free Cash Flow OCF − CapEx | $-17.63M | $46.01M | $40.15M | $22.58M |
Shares Outstanding | 49.42M | 50.30M | 50.16M | 49.75M |